. 2021 Nov 5;10(12):1570–1583. doi: 10.1530/EC-21-0398

Table 3.

Correlation of both baseline and DELTA changes of ANGPTL3, 4 and 8 with corresponding studied clinical and laboratory data among all baseline study groups and naïve and treated hypothyroid patients. Spearman’s or Pearson’s correlation determines the relation between ANGPTL and cardio-metabolic risk factor among naïve patients and LT4 (thyroxin replacement therapy) patients.

Naïve patients			Age (years)	BMI (kg/m²)	WC (cm)	SBP (mmHg)	DBP (mmHg)	TSH (IU/mL)	FT3 (pg/mL)	FT4 (ng/dL)	TPO (IU/mL)	FPG (mg/dL)	Insulin (mU/mL)	Homa-IR	HDL-c (mg/dL)	LDL-c (mg/dL)	Total C (mg/dL)	TG (mg/dL)	hsCRP (mg/L)
ANGPTL3 (ng/ml)	all	r	0.02	0.52^b	0.01	0.39^b	0.44^b	0.71^b	−0.6^b	−0.73^b	0.74^b	0.26^b	0.54^b	0.57^b	−0.33^b	0.78^b	0.81^b	0.69^b	0.65^b
	SCH	r	−0.65^b	−0.27	−0.36^a	−0.41^a	−0.28	0.01	0.18	−0.01	−0.05	0.19	0.39^a	0.44^b	0.32	0.23	0.45^b	−0.38^a	−0.03
	OH	r	−0.48^b	−0.38^a	0.19	0.31	−0.02	0.04	0.16	−0.12	−0.02	−0.11	0.20	0.23	0.08	0.12	−0.01	−0.22	−0.04
ANGPTL4 (ng/mL)	all	r	0.3^b	0.65^b	0.18	0.6^b	0.52^b	0.7^b	−0.7^b	−0.78^b	0.71^b	0.30^b	0.50^b	0.53^b	−0.34^b	0.77^b	0.82^b	0.81^b	0.68^b
	SCH	r	0.16	0.31	0.13	0.46^b	0.05	0.05	0.22	−0.01	−0.47^b	0.11	0.37^a	0.31	0.42^a	0.02	0.02	−0.03	−0.33^a
	OH	r	0.30	0.33^a	0.19	0.15	−0.05	0.22	−0.11	0.03	−0.05	−0.03	−0.29	−0.29	−0.03	0.26	0.35^a	0.29	0.09
ANGPTL8 (pg/mL)	all	r	0.21^a	0.61^b	0.12	0.48^b	0.5^b	0.67^b	−0.7^b	−0.77^b	0.76^b	0.31^b	0.49^b	0.52^b	−0.42^b	0.76^b	0.82^b	0.77^b	0.71^b
	SCH	r	−0.01	−0.01	−0.52^b	−0.28	0.14	−0.15	−0.07	0.12	0.27	0.41^a	−0.16	−0.16	0.42^a	0.07	0.29	−0.46^b	0.19
	OH	r	−0.22	−0.11	0.15	0.14	−0.02	0.14	−0.04	0.30	−0.21	−0.11	0.20	0.21	−0.5^b	−0.07	0.03	0.17	−0.03
LT4 patients				↓∆BMI (kg/m²)	↓∆WC (cm)	↓∆SBP (mmHg)	↓∆DBP (mmHg)	↓∆TSH (IU/ml)	↑∆FT3 (pg/ml)	↑∆FT4 (ng/dl)	↓∆ TPO (IU/ml)	↓∆FBS (mg/dl)	↓∆Insulin (mU/mL)	↓∆Homa-IR	↑∆HDLc (mg/dl)	↓∆LDL-c (mg/dl)	↓∆Total C (mg/dl)	↓∆TG (mg/dl)	↓∆hsCRP (mg/L)
↓∆ANGPTL3 (ng/mL)	SCH	r		0.01	0.01	0.26	0.33^a	0.14	0.36^a	0.52^a	0.09	−0.04	−0.04	−0.04	0.1	−0.12	−0.23	−0.09	0.03
↓∆ANGPTL3 (ng/mL)	OH	r		−0.22	−0.45^b	0.09	0.41^a	0.44^a	0.12	0.13	0.26	−0.16	0.20	0.18	−0.13	0.16	−0.05	−0.35^a	−0.29
↓∆ANGPTL4 (ng/mL)	SCH	r		0.07	−0.11	0.26	0.19	0.18	0.04	0.17	−0.53^b	0.38^a	−0.09	−0.09	−0.1	−0.03	0.02	−0.41^a	0.19
↓∆ANGPTL4 (ng/mL)	OH	r		0.18	−0.22	0.14	0.241	−0.19	−0.5^b	0.23	−0.06	−0.05	−0.54^b	−0.5^b	−0.01	0.14	0.12	−0.05	−0.12
↓∆ANGPTL8 (pg/mL)	SCH	r		−0.34^a	−0.27	0.21	0.26	−0.4^a	0.12	0.27	0.13	0.06	−0.16	−0.19	0.29	0.03	−0.14	0.22	−0.16
↓∆ANGPTL8 (pg/mL)	OH	r		−0.33^a	−0.54^b	0.37^a	0.01	0.05	−0.17	0.05	0.22	−0.10	0.21	0.23	−0.30	0.28	0.09	−0.32	−0.11

Data given as r- correlation; significant P values: ^aP < 0.05 and ^bP < 0.01.

all, entire study population; ANGPTL, angiopoietin-like protein; C, cholesterol; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HOMA- IR, homeostatic model assessment of insulin resistance; HDL, high density lipoprotein; hsCRP, high sensitive c reactive protein; LDL, low density lipoprotein; OH, overt hypothyroidism; SBP, systolic blood pressure; SCH, subclinical hypothyroidism; TG, triglyceride; TPO, thyroid peroxidase antibody; WC, waist circumference; ↓∆, delta decreased level during follow-up; ↑∆, delta increased level during follow-up.